Tinnitus, Deafness and Ear Problems Support Group
This group is for those coping with Tinnitus (ringing ears or ear noise), hearing loss, and all ear issues. Join to find support and get advice from others.
MicroTransponder Fall Update
September 24, 2010
NIH NIDCD Awards a $2.65 Million Grant for 30-Patient Tinnitus Clinical Trial
MicroTransponder has received notice of a $2.65 Million grant from the National Institutes of Health (NIH) National Institute on Deafness and Other Communication Disorders (NIDCD). This grant will fund a 30-patient clinical trial in the U.S. starting in 2013. The research team at the Company is grateful to the U.S. academic research community for the support of our efforts to develop a novel treatment for tinnitus. We will be using our Serenity System in the clinical trial to deliver Paired Stimulation Therapy, where small bursts of stimulation are applied to the vagus nerve in the neck as the patient hears non-tinnitus tones via headphones. Additional information will be published on our website www.microtransponder.com and www.clinicaltrials.gov in the coming months.
U.S. Military 30-patient Trial Contract Awarded $3M (est.)
We have been informed that we are scheduled to be awarded a BAA 12-1 contract from the United States Army Medical Research and Materiel Command (USAMRMC) for a 30-patient tinnitus trial with active Department of Defense (DoD) members including the Army, Navy, and Air Force personnel. Tinnitus is currently the #1 disability in the U.S. Military with over 840,000 Veterans listing tinnitus as a disability. We are honored to be working with these American Heroes who have sacrificed so much for our Country.
UT Dallas / UT Southwestern Grants for U.S. Tinnitus and Stroke Trials
MicroTransponder will be receiving two grants from UT Dallas (UTD). Funding for these grants comes from a UTD fund designated to support translational research, bringing therapies from the University Lab into the clinic. Pursuant to these grants, UT Dallas/Southwestern will become a 4th site for the NIH 30-patient trial and will become the site for a standalone 10-patient stroke trial.
MicroTransponder Presents Positive Tinnitus Clinical Data at TRI Conference
The Company presented data from the initial 10-patient tinnitus clinical trial in June at the Tinnitus Research Initiative conference in Belgium. Patients with tinnitus were treated using a novel paired vagus nerve stimulation therapy which pairs listening to tones with small bursts of stimulation to the vagus nerve in the neck. The results for this initial trial were positive and many of the patients experienced a reduction in the severity and perception of tinnitus. The principal clinical investigator, Dr. Dirk De Ridder stated, The results from this initial clinical trial are promising, this therapy may be the first operative neuromodulation treatment capable of targeting the brain changes related to tinnitus in a controlled way. We look forward to additional longer term clinical trials.
Tinnitus Therapy featured in the American Tinnitus Associations magazine Tinnitus Today (Summer 2012 Research Edition)
It was an honor to be selected by the American Tinnitus Association (ATA) for a story in their annual research issue of their magazine Tinnitus Today. The ATA is the largest tinnitus patient group in the U.S. The article discussed the clinical success in the European trials and the new U.S. studies that will begin in 2013. The full article can be found at the following link on the ATA website: MTI in ATA Magazine.
Additional Grants Require Additional Angel Funding - $1.2M
The Company is pleased to announce that on May 31, MicroTransponder closed on $2 Million of angel funding. This funding was designed to enable the Company to support 2 smaller trials in tinnitus and stroke. The grants from the NIH, UTD, and U.S. Army are large in fiscal size, but the funds are primarily earmarked for the clinical trial sites and supporting staff. The Company has the prospect of having 4 clinical trials with 90 patients (60 for tinnitus and 30 for stroke) all running simultaneously in 2013 and 2014.
MicroTransponder needs to raise an additional $1.2 Million in order to allow our team to support these clinical trials uninterrupted through the end of Q1 2015. We sincerely hope that additional accredited investors will consider investing at this important juncture. Please email jordan@microtransponder.com for more information on investing or click here.
Management Team Members Switching Roles as Company Shifts Focus from Research to Clinical Trials
Note from Jordan Curnes President, COO: MicroTransponders Co-Founders, CEO Will Rosellini and Chairman Frank McEachern have decided to switch their titles at MicroTransponder as a result of the Companys recent transition to being fully focused on clinical trials. McEachern and Rosellini both founded MicroTransponder in 2007 and have been involved in all areas of the Company. McEachern has been taking the lead in directing the work of the engineering, regulatory, clinical, and legal teams in the past 2 years and will continue this work as CEO of MicroTransponder. Rosellini will continue to provide strategic input to the Company and will continue to be intimately involved in the day to day research and grant efforts of the Company. Rosellini is also taking a position with another non-competitive company focused on patent monetization.
September 24, 2010
NIH NIDCD Awards a $2.65 Million Grant for 30-Patient Tinnitus Clinical Trial
MicroTransponder has received notice of a $2.65 Million grant from the National Institutes of Health (NIH) National Institute on Deafness and Other Communication Disorders (NIDCD). This grant will fund a 30-patient clinical trial in the U.S. starting in 2013. The research team at the Company is grateful to the U.S. academic research community for the support of our efforts to develop a novel treatment for tinnitus. We will be using our Serenity System in the clinical trial to deliver Paired Stimulation Therapy, where small bursts of stimulation are applied to the vagus nerve in the neck as the patient hears non-tinnitus tones via headphones. Additional information will be published on our website www.microtransponder.com and www.clinicaltrials.gov in the coming months.
U.S. Military 30-patient Trial Contract Awarded $3M (est.)
We have been informed that we are scheduled to be awarded a BAA 12-1 contract from the United States Army Medical Research and Materiel Command (USAMRMC) for a 30-patient tinnitus trial with active Department of Defense (DoD) members including the Army, Navy, and Air Force personnel. Tinnitus is currently the #1 disability in the U.S. Military with over 840,000 Veterans listing tinnitus as a disability. We are honored to be working with these American Heroes who have sacrificed so much for our Country.
UT Dallas / UT Southwestern Grants for U.S. Tinnitus and Stroke Trials
MicroTransponder will be receiving two grants from UT Dallas (UTD). Funding for these grants comes from a UTD fund designated to support translational research, bringing therapies from the University Lab into the clinic. Pursuant to these grants, UT Dallas/Southwestern will become a 4th site for the NIH 30-patient trial and will become the site for a standalone 10-patient stroke trial.
MicroTransponder Presents Positive Tinnitus Clinical Data at TRI Conference
The Company presented data from the initial 10-patient tinnitus clinical trial in June at the Tinnitus Research Initiative conference in Belgium. Patients with tinnitus were treated using a novel paired vagus nerve stimulation therapy which pairs listening to tones with small bursts of stimulation to the vagus nerve in the neck. The results for this initial trial were positive and many of the patients experienced a reduction in the severity and perception of tinnitus. The principal clinical investigator, Dr. Dirk De Ridder stated, The results from this initial clinical trial are promising, this therapy may be the first operative neuromodulation treatment capable of targeting the brain changes related to tinnitus in a controlled way. We look forward to additional longer term clinical trials.
Tinnitus Therapy featured in the American Tinnitus Associations magazine Tinnitus Today (Summer 2012 Research Edition)
It was an honor to be selected by the American Tinnitus Association (ATA) for a story in their annual research issue of their magazine Tinnitus Today. The ATA is the largest tinnitus patient group in the U.S. The article discussed the clinical success in the European trials and the new U.S. studies that will begin in 2013. The full article can be found at the following link on the ATA website: MTI in ATA Magazine.
Additional Grants Require Additional Angel Funding - $1.2M
The Company is pleased to announce that on May 31, MicroTransponder closed on $2 Million of angel funding. This funding was designed to enable the Company to support 2 smaller trials in tinnitus and stroke. The grants from the NIH, UTD, and U.S. Army are large in fiscal size, but the funds are primarily earmarked for the clinical trial sites and supporting staff. The Company has the prospect of having 4 clinical trials with 90 patients (60 for tinnitus and 30 for stroke) all running simultaneously in 2013 and 2014.
MicroTransponder needs to raise an additional $1.2 Million in order to allow our team to support these clinical trials uninterrupted through the end of Q1 2015. We sincerely hope that additional accredited investors will consider investing at this important juncture. Please email jordan@microtransponder.com for more information on investing or click here.
Management Team Members Switching Roles as Company Shifts Focus from Research to Clinical Trials
Note from Jordan Curnes President, COO: MicroTransponders Co-Founders, CEO Will Rosellini and Chairman Frank McEachern have decided to switch their titles at MicroTransponder as a result of the Companys recent transition to being fully focused on clinical trials. McEachern and Rosellini both founded MicroTransponder in 2007 and have been involved in all areas of the Company. McEachern has been taking the lead in directing the work of the engineering, regulatory, clinical, and legal teams in the past 2 years and will continue this work as CEO of MicroTransponder. Rosellini will continue to provide strategic input to the Company and will continue to be intimately involved in the day to day research and grant efforts of the Company. Rosellini is also taking a position with another non-competitive company focused on patent monetization.
We are getting close.